News (204)

Alnylam Issues 2023 Corporate Responsibility Report BU
Alnylam Pharmaceuticals : 2023 REPORT PU
Transcript : Alnylam Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity BU
Transcript : Alnylam Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 09:10 AM
Transcript : Alnylam Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity BU
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen's Association AQ
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association BU
Transcript : Alnylam Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 09:45 AM
Alnylam Announces Preliminary Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates AQ
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 09:30 AM
Transcript : Alnylam Pharmaceuticals, Inc. Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-14-2023 10:00 AM
Transcript : Alnylam Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis BU
Transcript : Alnylam Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 03, 2023
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Roche to co-develop hypertension RNAi therapeutic AQ
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk GL
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk BU
Transcript : Alnylam Pharmaceuticals, Inc., Q1 2023 Earnings Call, May 04, 2023
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity BU
Alnylam Issues 2022 Corporate Responsibility Report BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy BU
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy GL
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy AQ
PACIRA BIOSCIENCES, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure (form 8-K) AQ
Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors GL
Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors AQ
Pacira Biosciences Announces Yvonne Greenstreet to Retire from Board of Directors CI
Alnylam Announces Appointment of Peter Kellogg to Board of Directors BU
Transcript : Alnylam Pharmaceuticals, Inc., Q4 2022 Earnings Call, Feb 23, 2023
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity BU
Transcript : Alnylam Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 09:45 AM
Alnylam Announces Preliminary Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates AQ
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates BU
Alnylam Announces Updates to its Board of Directors BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Alnylam Ranks 1 on Boston Globe's Top Places to Work List for 2022 AQ
1234NextSee all

Insiders

Picture Yvonne Greenstreet
Yvonne Greenstreet

Yvonne L. Greenstreet founded Highgate LLC. Currently, Dr. Greenstreet is President & Chief Operating Officer of Alnylam Pharmaceuticals, Inc. Dr. Greenstreet is also on the board of Pacira Biosciences, Inc. and Member of The Association of the British Pharmaceutical Industry. Dr. Greenstreet previously occupied the position of Managing Director at Highgate LLC, Senior Vice President & Head-Medicines Development at Pfizer Inc. and Chief Strategy-R&D, Senior Vice President at GlaxoSmithKline Plc. Yvonne L. Greenstreet received an MBA from INSEAD and an undergraduate degree from the University of Leeds.


Picture Michelle M. Greenstreet
Michelle M. Greenstreet

Michelle M.
Greenstreet
formerly worked at Citibank NA (New York), as Senior Vice President & Director-Human Resource, United Parcel Service, Inc., as Principal, Texas Workforce Commission, as Principal, Caliber Home Loans, Inc., as Chief Human Resources Officer & Executive VP from 2012 to 2014, Vericrest Financial, Inc., as Chief Human Resources Officer, and Spirit Realty Capital, Inc., as Chief Administrative Officer & Executive VP.
Ms. Greenstreet received her undergraduate degree from Texas A&M University.








Picture Ian Greenstreet
Ian Greenstreet

Ian O.
Greenstreet
is the founder of Infinity Capital Partners Ltd.
He currently holds positions as an Independent Non-Executive Director at The Principality Building Society and at Simmons & Simmons LLP.
Previously, he held positions as an Independent Non-Executive Director at Lesaka Technologies, Inc., an Independent Director at Diamond Bank Plc, and as a Director & Head at Henderson Fund Management (Luxembourg) SA, among others.
He received his undergraduate degree from The University of Manchester.




Picture James John Pryn Greenstreet
James John Pryn Greenstreet

James John Pryn Greenstreet is the founder of Newmarket Capital Ltd.
which was founded in 2001 where he holds the title of Head-Corporate Finance.
He currently holds the position of Director at CityJet DAC and Electric Aviation Group Ltd.
Additionally, he is the Executive Vice President at Falko Regional Aircraft Ltd.
since 2011.
Mr. Greenstreet's former positions include being a Non-Executive Director at Powerhouse Energy Group Plc from 2021 to 2022, an Independent Non-Executive Director at Powerhouse Energy Group Plc from 2011 to 2021, and a Principal at BAE Systems Plc, IBM United Kingdom Ltd., XL Capital Assurance (UK) Ltd., and Arthur Andersen (UK).



Picture Michael Greenstreet
Michael Greenstreet

Michael Greenstreet currently works as a Director for Easter Seals New Jersey, Inc.







Picture Yvonne Austin
Yvonne Austin

Yvonne Austin currently works as a Director at The Home of the Innocents, Inc.


Picture Yvonne Helbert
Yvonne Helbert

Ms. Yvonne Helbert is Scientist at The Courtagen Group LLC.
Prior to joining Courtagen, she was a Senior Development Scientist at Beckman Coulter Genomics (formerly Agencourt Bioscience).
While there she was part of a team that developed and validated The Agencourt Genfind v2 gDNA Isolation Kit and Viral Nucleic Extraction Kit.
She was also a key member of the Molecular Diagnostics Research and Development team.
Ms. Helbert was also a Senior Laboratory Technician at The Center of Human Genetics at Boston University School of Medicine.
There she performed over a half a million genotype experiments on samples from more than three thousand patients.
She also built the laboratory’s mass spectrometry program for single nucleotide polymorphism detection, and she was responsible for all such experiments conducted in the lab.
Ms. Helbert received her Bachelor’s degree in Biology from Syracuse University and Master’s degree in Biochemistry from Boston University School of Medicine.








Picture Yvonne Deeney
Yvonne Deeney

Yvonne Deeney is a Non-Executive Director at Tokio Marine Global Re Ltd.
She was previously an Independent Non-Executive Director at Masawara Plc from 2011 to 2018.
Prior to that, she was the Managing Director at GE Re Management Services Ltd.
from 1998 to 2004.
She also held the position of Head-Fixed Income Investments at Gulf International Bank (UK) Ltd.



Picture Yvonne McLeod
Yvonne McLeod

Yvonne McLeod is currently a Member at the Association of Professional Engineers & Geoscientists of AB and SVP-Drilling, Completions, HSE & Regulatory at Pieridae Energy Ltd.
Previously, she worked as Senior Vice President-Engineering at Ikkuma Resources Corp.
and Vice President-Drilling & Facilities at Manitok Energy, Inc. from 2013 to 2014.
Ms. McLeod obtained her undergraduate degree from the University of Calgary.




Picture Yvonne Leach
Yvonne Leach

Yvonne Leach currently works at Mountain Vista Health Park, Inc., as Director-Nursing Services.






Picture Yvonne Sharpe
Yvonne Sharpe

Yvonne Sharpe is the Director of Administration at XSeed Capital, and joined the firm in 2006.
Prior to XSeed, Yvonne was a Senior Executive Administrator at Burns McClellan, a New York Public Relations firm, where she worked with the Chief Executive Officer to focus on internal operations, including firm-wide evaluations, promotion processes, and recruiting procedures, and instituted a training program for the junior associates.
Before going to New York, Yvonne spent seven years as office manager of Petkevich and Partners, a start-up investment bank.
She implemented all office policies, procedures, and fiscal controls, administered Central Registration Depository / National Association of Securities Dealers requirements, and worked closely with the Managing Directors.
In her 20 year administrative career, Yvonne has also worked with the Corporate Finance Director at Robertson Stephens, the Managing Director of the Western Region at the MAC Group / Gemini Consulting, and the Vice Chairman at Marakon Associates.



Picture Yvonne Lomax
Yvonne Lomax

Yvonne Lomax is currently working as a Controller at Technology Ventures, Inc. She previously worked as an Analyst-Budget & Purchasing at Raytheon Co.















Picture Yvonne J. Camacho
Yvonne J. Camacho

Yvonne J.
Camacho
is currently the Treasurer & Director at The Kempe Foundation for the Prevention & Treatment since 2013.
She is also currently a Director at BackEndB.com LLC since 2019, a Director at BackendB.com Holding Corp., and a Trustee at Mercy Housing, Inc. Additionally, Ms. Camacho previously worked as an Executive Vice President-Finance & Administration at Simpson Housing LLLP.
She completed her undergraduate degree at The University of Colorado.





Picture Yvonne Zeoli
Yvonne Zeoli

Yvonne Zeoli worked as a Sales Assistant at IKON Office Solutions, Inc. from 1997 to 2002 and as a Senior Plan Consultant at Freedom One Financial Group LLC from 2003 to 2012.










Picture Yvonne Higgins
Yvonne Higgins

Yvonne Higgins worked as an Executive Director of Human Research Protections at the University of Pennsylvania from 2004 to 2011.
She also worked as a Vice President of Quality Management at The Copernicus Group, Inc. Additionally, she served as a Council Member at the Association for Accreditation of Human Research Protection Programs, Inc. from 2009 to 2011.
Ms. Higgins received an undergraduate degree from Hood College.



Picture Yvonne Chien
Yvonne Chien

Yvonne Chien held several positions in different companies throughout her career.
She was a Senior Vice President of Marketing at Getty Images, a Principal at Google LLC, Abcam Plc, Bebo, Inc., and Brainjuicer Ltd.
She obtained an undergraduate degree from the University of California, Berkeley, and an MBA from Harvard Business School.




Picture Yvonne Goldsberry
Yvonne Goldsberry

Yvonne Goldsberry is currently the Director at Goodwill Industries of Northern New England, Director at Savings Bank of Walpole, and President at The Endowment for Health.
She previously worked as the VP-Population Health & Clinical Integration at Cheshire Medical Center.


Picture Yvonne Soeder
Yvonne Soeder

Yvonne Soeder worked as a Co-Secretary at Rhön-Klinikum AG.






Picture Yvonne Hallén
Yvonne Hallén

Yvonne Hallén worked as an Administration Manager at ONCOlog Medical QA AB from 2002 to 2013.




Picture Yvonne Bakkehaugen
Yvonne Bakkehaugen

Mrs. Yvonne Bakkehaugen joined Norvestor Equity AS in 2008 .
Her former positions include Analyst at Fox-Pitt, Kelton (London) and Sales Coordinator with ACTA She holds an M.
Sc in Business Administration from The Norwegian School of Economics and Business Administration.






Picture Yvonne Y. F. Chan
Yvonne Y. F. Chan

Yvonne Y.
F.
Chan
is currently working as Counsel at Paul, Weiss, Rifkind, Wharton & Garrison LLP.






Picture Yvonne Sneddon
Yvonne Sneddon

Yvonne Sneddon is currently the Chairman of Flinders Reproductive Medicine Pty Ltd., Director of Motor Accident Commission, Director of South Australian Government Financing Authority, Director of Return to Work Corporation of South Australia, Director of Unity Housing Co. Ltd., Director of ReturnToWorkSA, and Director of Tax Practitioners Board.
She previously served as Representative Director of Statewide Superannuation Pty Ltd., Director of SAGE Group Holdings Ltd., and Director of Sage Automation Pty Ltd.



Picture Yvonne Garcia
Yvonne Garcia

Yvonne Garcia is currently the Director at the John F.
Kennedy Library Foundation.
Previously, she served as the Chairman at The Association of Latino Professionals in Finance & Accounting and as the Director at The Partnership, Inc. She holds an MBA from Boston University and an undergraduate degree from the State University of New York at Albany.





Picture Yvonne Zwane
Yvonne Zwane

Yvonne Zwane is currently the Group Chief Executive Officer at Ithala Development Finance Corp.
Ltd.


Picture Yvonne Siebert
Yvonne Siebert

Yvonne Siebert has a current job as a Member-Supervisory Board at SMA Solar Technology AG.


Picture Yvonne Wassenaar
Yvonne Wassenaar

Yvonne L.
Wassenaar
is currently serving as the Chairman at Redbird SAS.
She is also an Independent Director at Forrester Research, Inc., Harvey Mudd College, Arista Networks, Inc., JFrog Ltd., Rubrik, Inc., and SGNL.ai, Inc. Additionally, she holds positions as a Director at Athenaalliance and Fika Management LLC, and as a Fund Advisor at Fika Management LLC.
Ms. Wassenaar is a Limited Partner at Operator Collective Management LLC.
In her former roles, Ms. Wassenaar served as the Chief Executive Officer & Director at Unmanned Innovation, Inc. from 2017 to 2018.
She was also the Chief Executive Officer & Director at Puppet, Inc. from 2019 to 2022.
Ms. Wassenaar served as a Director at MuleSoft LLC from 2017 to 2018 and as an Independent Director at Anaplan, Inc. from 2019 to 2022.
She has also held positions as a Director at Bitium, Inc. and as a Partner at Accenture Plc.
Ms. Wassenaar worked as the Vice President-Strategy & Enablement at VMware, Inc. from 2010 to 2014 and as the Chief Information Officer & Senior VP-Operations at New Relic, Inc. from 2014 to 2017.
She served as an Advisor at Snyk Ltd.
from 2018 to 2020 and at StackHawk, Inc. from 2020 to 2022.
Ms. Wassenaar completed her undergraduate studies at the University of California, Los Angeles.
She also holds an MBA from UCLA Anderson School of Management.


No results for this search

  1. Stock Market
  2. Advanced search
  3. Yvonne Greenstreet